Ghoul
Well-known Member
Completely by coincidence, I was reading a study looking at HGH injection pain, and they consider reducing injection volume as a strategy, since sub-q injections over 1ml are known to be painful, but as I noted, high concentration speeds up degradation of peptides (and proteins) by forming aggregates.There isn't great science on this but for 10 IU vials, I add 2 mL BAC and shoot it in two 1 mL subQ shots daily.
In the absence of better evidence, I'm siding with more diluted rather than more concentrated (for other peptides too).
One approach to reducing the injection volume is to increase hGH concentration. However, as mentioned previously, highly concentrated hGH formulations have higher viscosity and thus a higher risk of aggregate or insoluble particulate formation, compromising product stability and safety.
The compromised "safety" they mention is the immune reaction to the aggregates which causes immunity to HGH and even natural growth hormone to develop (this happens in about 2% of patients, who have to stop treatment. I'll bet there's an even higher percentage of people using UGL who don't realize they've developed immunity to HGH, it just "doesn't work", or they need really high doses).
They conclude that whatever the total HGH dose, it should "fit" into 0.5-.8ml, which is well above the minimum dilution of any dose (even BB doses), but also provides the right pharmacokinetics, allowing HGH to absorb into the body at the ideal rate, with minimal pain:
According to these results, injection volumes ≤ 1.0 mL are preferred, and 0.5-0.8 mL is ideal.
Frontiers | New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain
Reducing injection-site pain (ISP) in patients with chronic conditions such as growth hormone deficiency is a valuable strategy to improve patient compliance...
www.frontiersin.org